Abstract
Significance Cannabis pharmaceuticals have experienced dramatic growth in recent years as regulatory approvals have increased. The sector’s expansion deepens contradictions within the international system of illicit narcotics control, and in national laws that limit medical access and criminalise ‘recreational’ cannabis use. Impacts Pressure on national governments and the international control system to address legal and regulatory contradictions will increase. Cannabis-cultivating states in the developing world, excluded from European and US supply and innovation chains, will agitate for reform. The pharmaceutical cannabis ‘green rush’ and mergers and acquisitions in the legal recreational sector will fuel ‘corporatisation’ fears.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
